MarketCap
Facebook
X
Telegram
X4 Pharmaceuticals EBITDA | XFOR
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA X4 Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -85.6 M | -35.6 M | -107 M | -87.1 M | -84.6 M | -59.5 M | -51.6 M | -42.6 M | -31.9 M | -21.6 M | -12.4 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.4 M | -107 M | -56.3 M |
Quarterly EBITDA X4 Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20 M | -16.4 M | -20.3 M | -23.8 M | -27.3 M | -26.1 M | -9.15 M | -35.5 M | -34.3 M | 71.2 M | -37.2 M | -25.2 M | -27.2 M | - | -29.2 M | -16.8 M | -29.2 M | -20.4 M | -21.1 M | -28.9 M | -19 M | -18.9 M | -17.8 M | -17.6 M | -16.8 M | -14.6 M | -10.5 M | -10.8 M | -16.9 M | -13.4 M | -10.4 M | -8.03 M | -8.52 M | -6.35 M | -6.08 M | - | -12.9 M | -5.55 M | -5.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71.2 M | -37.2 M | -16.1 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Oramed Pharmaceuticals
ORMP
|
-15 M | $ 3.97 | -0.75 % | $ 164 M |  Israel |
 |
Tyme Technologies
TYME
|
-25.5 M | - | 8.07 % | $ 54 M |  USA |
 |
Puma Biotechnology
PBYI
|
48.2 M | $ 8.13 | -3.22 % | $ 407 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-31.5 M | $ 1.02 | -5.09 % | $ 47.3 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-3.21 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Pfizer
PFE
|
6.59 B | $ 29.34 | 0.36 % | $ 167 B | USA |
 |
Завод ДИОД
DIOD
|
85.9 M | - | - | - |  Russia |
 |
PainReform Ltd.
PRFX
|
-5.11 M | $ 0.78 | -4.24 % | $ 505 K | Israel |
 |
Prothena Corporation plc
PRTA
|
-214 M | $ 8.56 | -2.51 % | $ 461 M | USA |
 |
Arcus Biosciences
RCUS
|
-376 M | $ 18.66 | -1.56 % | $ 2 B | USA |
 |
Orgenesis
ORGS
|
-37.7 M | - | -33.86 % | $ 61.2 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
71.8 B | $ 14.9 | -1.03 % | $ 12.4 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
4.12 B | $ 916.16 | -0.41 % | $ 95.8 B | USA |
 |
Replimune Group
REPL
|
-317 M | $ 23.3 | 4.67 % | $ 2.16 B | USA |
 |
Фармсинтез
LIFE
|
-22.6 M | - | - | - | Russia |
 |
Royalty Pharma plc
RPRX
|
1.56 B | $ 69.47 | 1.02 % | $ 29.9 B | USA |
 |
Revolution Medicines
RVMD
|
-1.17 B | $ 193.0 | -3.57 % | $ 36.7 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-192 M | $ 113.99 | 0.04 % | $ 7.41 B | USA |
 |
Codiak BioSciences
CDAK
|
-64.2 M | - | -55.98 % | $ 2.15 M | USA |
 |
Sana Biotechnology
SANA
|
-238 M | $ 2.43 | -1.42 % | $ 615 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-7.43 M | $ 61.81 | 0.11 % | $ 172 M | Israel |
 |
Summit Therapeutics
SMMT
|
146 K | $ 17.78 | -0.34 % | $ 13.3 B |  Britain |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-267 M | $ 9.43 | -0.89 % | $ 817 M | USA |
 |
Spero Therapeutics
SPRO
|
6.31 M | $ 1.01 | -5.61 % | $ 56.6 M | USA |
 |
Sarepta Therapeutics
SRPT
|
-655 M | $ 16.4 | -5.54 % | $ 1.64 B | USA |
 |
Tarsus Pharmaceuticals
TARS
|
-70.1 M | $ 73.9 | 4.32 % | $ 3.09 B | USA |
 |
Bio-Techne Corporation
TECH
|
349 M | $ 72.83 | -0.01 % | $ 11.4 B | USA |
 |
Sage Therapeutics
SAGE
|
-431 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
49.8 M | - | - | $ 1.62 B | Israel |
 |
Cabaletta Bio
CABA
|
-171 M | $ 1.43 | -5.0 % | $ 144 M | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-172 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
16.3 M | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
1.01 B | - | - | $ 26.6 B |  Irlanda |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-124 M | $ 4.12 | -8.35 % | $ 35.1 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-45.7 M | - | - | $ 121 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-144 M | $ 11.55 | 4.52 % | $ 1.61 B |  France |
 |
Gilead Sciences
GILD
|
10.4 B | $ 170.68 | 0.8 % | $ 212 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-109 M | $ 4.28 | -2.06 % | $ 1.37 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-43.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-30.3 M | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-158 M | - | - | $ 411 M | USA |
 |
Gossamer Bio
GOSS
|
-171 M | $ 11.2 | 5.21 % | $ 2.56 B | USA |
 |
GeoVax Labs
GOVX
|
-21.6 M | $ 0.11 | -22.17 % | $ 105 K | USA |
 |
United Therapeutics Corporation
UTHR
|
1.58 B | $ 588.33 | 1.01 % | $ 26.1 B | USA |
 |
Seelos Therapeutics
SEEL
|
-40.5 M | - | -47.76 % | $ 6.27 M | USA |
 |
Vericel Corporation
VCEL
|
22.6 M | $ 59.02 | 1.08 % | $ 2.97 B | USA |
 |
Veracyte
VCYT
|
79.2 M | $ 24.05 | -7.21 % | $ 1.89 B | USA |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | USA |